Curia Executive and Leadership Team

Philip Macnabb, the Chief Executive Officer at Curia, directs the overarching corporate strategy for this contract research, development, and manufacturing organization. Macnabb oversees the integration of R&D services with commercial manufacturing capabilities to support global pharmaceutical clients. By aligning internal resources with market demands, the Chief Executive Officer ensures the company maintains a competitive edge in the complex biopharmaceutical landscape. Philip Macnabb drives the expansion of service offerings across North American and international markets, focusing on long-term growth and operational efficiency. The Chief Executive Officer collaborates with the board to refine the organizational vision, ensuring that every facility adheres to rigorous quality standards. Through this leadership, the company optimizes its service delivery model, providing essential support to drug developers from early-stage research through final commercial production. Macnabb maintains a focus on scaling infrastructure to meet the evolving needs of the global life sciences sector.

Alex Milenkovic, the Founder & Chief Executive Officer at Curia, architects the foundational vision and long-term strategic direction for the organization. Milenkovic focuses on the evolution of the company from a research-centric entity into a comprehensive partner for pharmaceutical and biopharmaceutical manufacturing. Alex Milenkovic drives the development of proprietary technologies and service platforms that distinguish the company within the competitive contract manufacturing market. The Founder & Chief Executive Officer oversees high-level partnerships, ensuring that the organization remains at the forefront of scientific advancement. By fostering a culture of innovation, the Founder & Chief Executive Officer guides the company through complex regulatory environments and global supply chain challenges. This leadership role involves identifying emerging market opportunities and directing capital investments toward high-growth areas. Milenkovic ensures that the company delivers consistent value to clients by maintaining a focus on technical expertise and reliable, scalable production processes across all global operations.

Gerald Auer, the Group Chief Financial Officer at Curia, directs the financial strategy, capital allocation, and fiscal reporting for the organization. Auer oversees the budgeting and forecasting processes that support the company's extensive R&D and commercial manufacturing operations. Gerald Auer drives the financial planning necessary to sustain growth and fund infrastructure investments across the company's global footprint. The Group Chief Financial Officer manages relationships with investors and financial institutions, ensuring the company maintains the liquidity required to execute its long-term business model. By implementing rigorous financial controls, the Group Chief Financial Officer ensures operational efficiency and profitability across all service lines. Auer collaborates with the executive team to evaluate potential acquisitions and strategic partnerships that enhance the company's market position. This leadership role involves monitoring economic trends and mitigating financial risks, providing the stability needed to support the complex, high-stakes requirements of the pharmaceutical and biopharmaceutical customers served by the organization.

Kourtney Forster, the President at Curia, directs the execution of core business operations and ensures the alignment of service delivery with client expectations. Forster oversees the cross-functional coordination between research, development, and manufacturing teams to ensure seamless project transitions. Kourtney Forster drives the operational excellence initiatives that improve throughput and quality across the company's diverse service portfolio. The President manages the day-to-day performance of key business units, ensuring that the organization meets the rigorous demands of pharmaceutical partners. By optimizing internal workflows, the President supports the company's ability to deliver products and services from early-stage R&D through to commercial scale. Forster leads efforts to streamline communication between departments, fostering a collaborative environment that accelerates project timelines. This leadership role involves managing operational risks and ensuring that all processes adhere to global regulatory standards, ultimately supporting the company's mission to provide reliable, high-quality solutions to the biopharmaceutical industry.

James Grabowski, the President, Research & Development at Curia, directs the scientific strategy and innovation pipeline for the company's research services. Grabowski oversees the laboratory operations and technical teams responsible for advancing client projects from initial discovery through development phases. James Grabowski drives the adoption of cutting-edge methodologies and technologies that enhance the company's capabilities in drug discovery and process development. The President, Research & Development manages the scientific talent pool, ensuring that the organization maintains the expertise required to solve complex pharmaceutical challenges. By fostering collaboration with internal manufacturing teams, the President, Research & Development ensures that research outcomes are successfully translated into scalable commercial processes. Grabowski leads the strategic planning for R&D investments, focusing on areas that provide the greatest value to biopharmaceutical customers. This leadership role ensures that the company remains a leader in scientific innovation, providing the foundational research necessary for the successful development of new therapeutic products.

Ronald Aungst, the President, Drug Product at Curia, directs the commercial manufacturing and drug product formulation operations. Aungst oversees the production facilities and supply chain logistics required to deliver high-quality pharmaceutical products to global customers. Ronald Aungst drives the implementation of advanced manufacturing technologies that ensure precision, safety, and compliance with international regulatory standards. The President, Drug Product manages the scaling of production processes, ensuring that the company can meet the volume requirements of its biopharmaceutical partners. By optimizing manufacturing workflows, the President, Drug Product improves operational efficiency and reduces time-to-market for client products. Aungst leads the quality assurance and technical teams responsible for maintaining the integrity of the drug product lifecycle. This leadership role involves coordinating with R&D and commercial teams to ensure that manufacturing capabilities align with the evolving needs of the pharmaceutical industry, ultimately supporting the company's mission to provide reliable, end-to-end manufacturing solutions.

Joseph Sangregorio, the Chief Human Resources Officer at Curia, directs the global talent strategy and organizational development initiatives. Sangregorio oversees the recruitment, retention, and professional growth of the scientific and manufacturing workforce essential to the company's R&D and production services. Joseph Sangregorio drives the implementation of performance management systems that align individual contributions with the broader corporate mission of supporting pharmaceutical innovation. The Chief Human Resources Officer manages complex labor relations and cultural integration across diverse geographic sites, ensuring a unified approach to operational excellence. By optimizing human capital, the Chief Human Resources Officer supports the company's ability to scale its workforce in response to increasing demand for biopharmaceutical services. Sangregorio leads initiatives to foster an inclusive environment that attracts top-tier scientific talent. This leadership role ensures that the organization maintains the specialized expertise required to navigate the rigorous demands of the pharmaceutical industry while promoting sustainable growth and employee engagement.

Gregory Kuzma, the Senior Vice President, Chief Information Officer at Curia, architects the digital infrastructure and cybersecurity frameworks supporting the company's global operations. Kuzma oversees the integration of advanced data analytics and information systems that facilitate seamless collaboration between R&D teams and commercial manufacturing units. Gregory Kuzma drives the modernization of IT platforms to ensure compliance with stringent pharmaceutical data integrity standards. The Senior Vice President, Chief Information Officer manages the technological roadmap, enabling the company to leverage digital tools for improved process efficiency and client transparency. By securing critical intellectual property and operational data, the Senior Vice President, Chief Information Officer protects the company's competitive position in the biopharmaceutical market. Kuzma leads the digital transformation efforts that allow the organization to scale its service delivery across international regions. This leadership role ensures that all technological investments directly support the company's mission of providing high-quality, reliable research and manufacturing services to global customers.